Dosage and administration
Noopept ® should be taken following meals. The normal daily dose is 20 mg: 10 mg twice daily (morning and afternoon). In case of insufficient efficacy and good tolerability the dose may be increased to 30 mg: 10 mg thrice daily. The duration of a course of treatment is 1.5 - 3 months. A second course of treatment, if necessary, can be carried out after discontinuing for 1 month.
Allergic reactions are possible. A rise in blood pressure may occur in patients with hypertension.
Specific manifestations of overdose have not been established.
Country of Manufacture: Russia
US Domestic shipping is available for this product! Choose Ships from: US size option to get it in 3-7 days to any US address. Dont forget to choose US Domestic Shipping when checking out.Noopept ® is one of many unique peptide nootropics that have been extensively studied in Russia, though until recently they were largely unknown in Western countries. From 1985 until 2006 there have been 76 studies published that focused on different applications of Noopept ® for treating various conditions in humans. In 2006, Noopept ® successfully finished the third phase of clinical trials and was approved as an OTC pharmaceutical. Since then, it is produced in one of the Pharmstandard factories (http://pharmstd.com) and is available in all Russian pharmacies.
Its effect is physiological to the human body, as it is based on the formation of active compound cyclopropyl glycine, which is naturally occurring in the brain. Noopept increases alpha/beta1 activity, with 30-min. latency and 40-min. duration in all brain areas. Unlike many other pharmaceuticals, Noopept ® can be officially used both for healthy individuals, who want to optimise their mental performance, and for those who have the following symptoms:
- Impaired memory formation
- Emotionally labile disorders
- Various brain injures
- Asthenic disorders (lack of energy)
- Other conditions characterised by reduced intellectual productivity
One pack of Noopept ® contains 50 pills, each with 10 mg of the active ingredient, which is sufficient for approximately 20 days of administration.
Country of Manufacture: RussiaAvailability: in stock
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease.
- Ostrovskaya et al (2002) The original novel nootropic and neuroprotective agent noopept https://www.ncbi.nlm.nih.gov/pubmed/12596521
- Molodavkin et al (2002) Effect of the novel dipeptide nootropic agent noopept and its metabolite cyclo-L-prolylglycine on the transcallosal evoked potential in the rat brain https://www.ncbi.nlm.nih.gov/pubmed/12109288
- Kovalenko et al (2002) Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111) https://www.ncbi.nlm.nih.gov/pubmed/12109295
- Kovalenko et al (2002) Preclinical study of noopept toxicity https://www.ncbi.nlm.nih.gov/pubmed/12025790
- Voronina et al (2005) Comparative study of the long-term behavioral effects of noopept and piracetam in adult male rats and female rats in postnatal period https://www.ncbi.nlm.nih.gov/pubmed/15934357
- Belnik et al (2007) Dipeptide preparation Noopept prevents scopolamine-induced deficit of spatial memory in BALB/c mice https://www.ncbi.nlm.nih.gov/pubmed/18214292
- Bel’nik et al (2007) Behavior of mice from different strains: modifications produced by noopept https://www.ncbi.nlm.nih.gov/pubmed/18064900
- Ostrovskaya et al (2007) The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model https://www.ncbi.nlm.nih.gov/pubmed/17092975
- Radionova et al (2008) Original nootropic drug noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade https://www.ncbi.nlm.nih.gov/pubmed/19145351
- Kravchenko et al (2009) The original nootropic and neuroprotective drug noopept potentiates the anticonvulsant activity of valproate in mice https://www.ncbi.nlm.nih.gov/pubmed/20095393
- G Neznamov, E Teleshova (2009) Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin https://www.ncbi.nlm.nih.gov/pubmed/19234797
- Kondratenko et al (2010) Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells https://www.ncbi.nlm.nih.gov/pubmed/20382202
- Amelin et al (2011) Noopept in the treatment of mild cognitive impairment in patients with stroke https://www.ncbi.nlm.nih.gov/pubmed/22500312
- Jia et al (2011) Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity https://www.ncbi.nlm.nih.gov/pubmed/21986202
- Ostrovskaya et al (2013) Efficiency of noopept in streptozotocin-induced diabetes in rats https://www.ncbi.nlm.nih.gov/pubmed/23484194
- Ostrovskaya et al (2014) Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422191/
- Povarov et al (2015) Nootropic dipeptide noopept enhances inhibitory synaptic transmission in the hippocampus https://www.ncbi.nlm.nih.gov/pubmed/25573367
- Vakhitova et al (2016) Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837574/
- Kolbaev et al (2018) Effect of Noopept on Dynamics of Intracellular Calcium in Neurons of Cultured Rat Hippocampal Slices https://www.ncbi.nlm.nih.gov/pubmed/29313229